BioXcel Therapeutics effectuates 1-for-16 reverse stock split effective Feb 7, 2025

BioXcel Therapeutics, Inc.

Board approved 1-for-16 reverse split on Jan 29; stockholders approved at Jan 28 special meeting.
Every 16 shares of common stock reclassified into 1 share; no fractional shares, cash paid for fractions.
Split-adjusted trading begins Feb 10 under existing symbol BTAI; new CUSIP 09075P204.
Proportional adjustments to equity plans, stock options, warrants, and other convertible securities.
Reverse split does not affect authorized shares or par value; shares remain fully paid and non-assessable.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BioXcel Therapeutics, Inc.: Approved a 1-for-16 reverse stock split of common stock via amendment to the Amended and Restated Certificate of Incorporation (effective 2025-02-07).

Change: charter amendment
Effective: 2025-02-07

Exact text from the filing

On February 6, 2025, BioXcel Therapeutics, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).

View on SEC.gov

Browse all governance changes →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-009906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.